As of 10:13 on April 14, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 4.65%, the constituent stocks Zai Lab (09688) rose 12.84%, East Sunshine Changjiang Pharmaceutical (01558) rose 9.04%, 3SBio (01530) rose 8.06%, BeiGene (06160), Akeso Biologics (09926) and other stocks followed suit. Hong Kong Pharmaceutical ETF (159718) rose 5.28%, hitting three consecutive gains. The latest price is quoted at 0.7 yuan. In the long run, as of April 11, 2025, Hong Kong stock pharmaceutical ETFs have risen by 21.88% in the past 3 months, ranking 2/4 of comparable funds.

In terms of liquidity, Hong Kong stock pharmaceutical ETFs changed hands by 24.25% intraday, with a turnover of 54.5722 million yuan, and the market was actively traded. In the long run, as of April 11, the average trading volume of Hong Kong stock pharmaceutical ETFs in the past one week was 89.5296 million yuan.

In terms of scale, the scale of Hong Kong-listed pharmaceutical ETFs has increased by 18.7946 million yuan in the past two weeks, achieving significant growth, and the new scale ranks 1/4 of comparable funds.

In terms of shares, the share of Hong Kong stock pharmaceutical ETFs has increased by 32 million shares in the past 1 week, achieving significant growth, and the new shares rank 2/4 of comparable funds.

In terms of fund inflows, the latest fund inflows and outflows of Hong Kong-listed pharmaceutical ETFs were flat. In the long run, there have been 4 net inflows of funds in the past five trading days, with a total of 36.6776 million yuan of "gold absorption", and an average daily net inflow of 7.3355 million yuan.

As of 10:13 on April 14, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 0.81%, the constituent stocks WuXi AppTec (603259) rose 3.19%, Shenzhou Cell (688520) rose 2.72%, Huahai Pharmaceutical (600521) rose 2.41%, Twining Biotech (301301) rose 2.25%, and Baike Biotech (688276) rose 2.00%. The Medical Innovation ETF (516820) rose 1.20%, hitting three consecutive gains. The latest price is 0.34 yuan. In the long run, as of April 11, 2025, the medical innovation ETF has risen by 5.70% in the past three months.

In terms of liquidity, the medical innovation ETF changed hands by 1.15% intraday, with a turnover of 19.2754 million yuan. In the long run, as of April 11, the average trading volume of medical innovation ETF in the past one week was 79.0238 million yuan.

In terms of scale, the latest scale of medical innovation ETF reached 1.661 billion yuan.

In terms of fund inflow, the latest net outflow of medical innovation ETF was 6.6627 million yuan. In the long run, there have been 3 net inflows of funds in the past five trading days, with a total of 28.8837 million yuan of "gold absorption", and an average daily net inflow of 5.7767 million yuan.

The data shows that leveraged funds continue to be deployed. The net purchase amount of medical innovation ETF in the previous trading day reached 1.9949 million yuan, and the latest financing balance reached 78.2772 million yuan.

GF Securities pointed out that the current focus of the capital market is quietly shifting from the traditional real estate and policy cycle to the more long-term strategic Sino-US technology game. We recommend paying attention to the allocation value of innovative drugs in Hong Kong stocks for the following reasons:1. Core logic 1: The global competitive advantage of China's innovative drugs going overseas is becoming prominent. 2. Core logic 2: The impact of the current tariff policy on innovative drugs is much smaller than that of other growth sectors. 3. Core logic 3: policy and regulatory attitudes have gradually shifted to a situation that is favorable to the sector. 4. Financial, Valuation and Transaction Data: Revenue growth, low valuations. 5. Transaction adequacy: The market pricing may not be sufficient for the fundamental repair of pharmaceuticals.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of March 31, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are WuXi Biologics (02269), BeiGene (06160), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), Sino Biopharma (01177), CSPC Pharmaceutical Group (01093), Zai Lab (09688), Ali Health (00241), and Hansoh Pharma ( 03692), the top 10 weighted stocks accounted for 59.76% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of March 31, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Mindray Medical (300760), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Huadong Medicine (000963), Changchun High-tech (000661), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.49%.